Human Biome Institute

Silver Sponsor

Human Biome S.A. (HBI) is a private company focused on developing cutting-edge Microbiome-Based Therapeutics. 

HBI combines breakthrough technologies and highly innovative microbiome knowledge in one unique approach to develop a pipeline of Next-Generation Live Biotherapeutic Products (LBPs) - Synthetic, Donor-independent, Autonomous Microbiome-Based Therapies. HBI uses advanced AI-machine learning algorithms and othe computational tools to analyze thousands of microbiome data within the TRAPP MicroBS module of Drug Discovery Platform (“MicroDrug”). As a result, the AI Platform identifies a pipeline of the New Generation Biotherapeutics (NGBs) and biomarkers.

Technologies developed by HBI:

• “MicroDrug®” - Drug Discovery AI Platform to predict microbiome drug composition
• “TRAPP MicroBS” - highly specialized in-silico platform to predict New Generation Biotherapeutics composition
• “Q Lab” - highly innovative, deep-tech in-vitro laboratory to synthesize New Generation Biotherapeutics
• “Mbiotix” - high-quality, high-richness, high-viability Fecal Microbiota Transplantation (FMT) preparation delivered to patients and used in clinical experiments as a proof of concept indications for NGBs
• Microbiome Biobank - A repository housing over 3,000 (to date) microbiome samples from healthy individuals and patients treated by Mbiotix (HBI's in-house manufactured FMT),
• Fecal Microbiota Transplantation (FMT) Clinical Platform & FMT Facility - A comprehensive FMT infrastructure, including a dedicated clinical platform, supports clinical trials led by HBI.

Human Biome pipeline includes:

• a flagship one: anti-ARB/AI NGB (anti-antibiotic resistant bacteria and anti-infective NGB)
• anti-CDI NGB (anti Clostridioides difficile NGB)
• immunoboosting NGB - enhancing immune function, particularly in preventing and treating post-transplant graft-versus-host disease (GvHD) and enhancing cancer immunotherapy response
• longevity/wellbeing dietary supplement - for promoting longevity and overall health and well-being.

The company was established in 2019. The Human Biome is one of the few in the world working in the field of the synthetic microbiome. HBI technology is the most advance to deliver the promise of safe and potent microbiome drugs. In the area of antimicrobial-resistance, we are the pioneers of developing prophylactic, antibiotic-resistnace genes and bacteria decolonizing drug, which shows excellent in silico and as proof-of-concept efficacy.

website